Nucleoside analogs plus ritonavir in stable antiretroviral therapy- experienced HIV-infected children: A randomized controlled trial

Sharon A. Nachman*, Kenneth Stanley, Ram Yogev, Stephen Pelton, Andrew Wiznia, Sophia Lee, Lynne Mofenson, Susan Fiscus, Mobeen Rathore, Eleanor Jimenez, William Borkowsky, Jane Pitt, Mary E. Smith, Barbara Wells, Kenneth McIntosh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

105 Scopus citations

Abstract

Context: Although protease inhibitors are used routinely in adults with human immunodeficiency virus (HIV) infection, the role of these drugs in the treatment of clinically stable HIV-infected children is not clear. Objective: To evaluate the safety, tolerance, and virologic response produced by a change in antiretroviral therapy in HIV-infected children who were clinically and immunologically stable while receiving previous therapy. Design: The Pediatric AIDS Clinical Trials Group 338, a multicenter, phase 2, randomized, open-label controlled trial conducted from February 6 to April 30, 1997 (patient entry period); patients were followed up for 48 weeks. Setting: Pediatric HIV research clinics in the United States and Puerto Rico. Patients: Two hundred ninety-seven antiretroviral-experienced, protease inhibitor-naive, clinically stable HIV-infected children aged 2 to 17 years. Interventions: Children were randomized to receive zidovudine, 160 mg/m2 3 times per day, plus lamivudine, 4 mg/kg 2 times per day (n = 100); the same regimen plus ritonavir, 350 mg/m2 2 times per day (n = 100); or ritonavir, 350 mg/m2 2 times per day, and stavudine, 4 mg/kg 2 times per day (n = 97). Main Outcome Measure: Plasma HIV-1 RNA levels at study weeks 12 and 48, compared among the 3 treatment groups. Results: At study week 12, 12% of patients in the zidovudine-lamivudine group had undetectable plasma HIV RNA levels (<400 copies/mL) compared with 52% and 54% of patients in the 2- and 3-drug ritonavir-containing groups, respectively (P<.001). Through study week 48, 70% of children continued receiving their ritonavir-containing regimen. At study week 48.42% of children receiving ritonavir plus 2 nucleosides compared with 27% of those receiving ritonavir and a single nucleoside had undetectable HIV RNA levels (P = .04); however, similar proportions in each group continuing initial therapy had HIV RNA levels of less than 10 000 copies/mL (58% vs 48%, respectively; P = .19). Conclusions: In our study, change in antiretroviral therapy to a ritonavir-containing regimen was associated with superior virologic response at study week 12 compared with change to a dual nucleoside analog regimen. More children receiving ritonavir in combination with 2 compared with 1 nucleoside analog had undetectable HIV RNA levels at study week 48.

Original languageEnglish (US)
Pages (from-to)492-498
Number of pages7
JournalJournal of the American Medical Association
Volume283
Issue number4
DOIs
StatePublished - Jan 26 2000

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Nucleoside analogs plus ritonavir in stable antiretroviral therapy- experienced HIV-infected children: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this